Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TheraCour-HSV1
- Development stage
- Preclinical
- Lead developer
- NanoViricides
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
TheraCour-HSV1 is a preclinical nanomedicine candidate being developed by NanoViricides for the treatment of Herpes Simplex Virus-1 (HSV-1) infections, specifically cold sores. Licensed from AllExcel and TheraCour Pharma, the drug utilizes the proprietary TheraCour polymeric micelle platform. These "nanoviricides" are engineered to mimic the receptors on a host cell's surface that the virus naturally targets. By acting as a decoy, the micelles bind to the virus particles (virions), effectively trapping and neutralizing them to prevent cellular entry and subsequent infection. This approach aims to provide a more effective alternative to traditional nucleoside analogues by directly targeting the extracellular virus particles.
- Other names
- TheraCour-HSV1-NanoViricidesTheraCour-HSV-1-NanoViricidesTheraCour-HSV 1-NanoViricides
02
Targets
Herpes simplex virus 1 envelope glycoprotein B and C heparan sulfate binding sitesHSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))
Beyond the preview
Go deeper on TheraCour-HSV1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TheraCour-HSV1.